Celcuity ( (CELC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celcuity’s stock experienced a positive surge due to the FDA’s acceptance of its new drug application for gedatolisib, aimed at treating advanced breast cancer. This milestone, coupled with promising Phase 3 results of its Geda Triplet Therapy and strong Q2 financial performance, has boosted investor confidence. As a result, there have been upward revisions in the stock’s price target, reflecting the company’s strong prospects and strategic progress.
More about Celcuity
YTD Price Performance: 276.69%
Average Trading Volume: 1,131,132
Technical Sentiment Signal: Buy
Current Market Cap: $2.1B
For further insights into CELC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.